Sign in Subscribe

ctdna

A collection of 97 issues

Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)

CRC Research Update — August 02, 2026

Today's colorectal cancer research highlights

Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients A Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79%

Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology) This content is informational only and does not constitute medical advice. Always

Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial

Skip to content The CRC Digest ◆ TRIAL DATA Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial A prospective, randomized phase III trial tested whether circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer patients. (Journal of Clinical Oncology) This content is informational only and

CRC Research Update — July 31, 2026

Today's colorectal cancer research highlights

Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery

Skip to content The CRC Digest ▪ SCREENING Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is

Blood-based surveillance after surgery increased curative treatment for recurrence

Skip to content The CRC Digest ▪ SCREENING Blood-based surveillance after surgery increased curative treatment for recurrence The phase III FIND trial showed that ctDNA methylation-guided surveillance in nonmetastatic colorectal cancer patients after surgery led to higher rates of curative-intent therapy for recurrence compared to standard CT-based monitoring. (Journal of Clinical